OUR PIPELINE

Temferon is a lenti-virus immuno therapy based on hematopoietic stem progenitor cell enabling controlled and targeted IFNa expresssion within the tumor microenvironment (TME) of solid tumors.  Engineered precursor stem cells produce tumor infiltrating monocytes (Tie2 expressing monocytes šC TEMs) that upon infiltrating solid tumors modify the  TME and allow the immune system to mount an anti-tumor response. Such biological evidence of resetting the TME in GBM patients allow Genenta to expand the study of Temferon in patients suffering from metastatic renal cell cancer and potentially in a broad range of solid tumors.